Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + GX in Resected Pancreatic Cancer
NCT06409429Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06409429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409429.